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ABSTRACT 
Adverse drug reaction (ADR), commonly termed as unwanted reaction is a long-
standing and a major medical problem that comes with many clinically important 
drugs. ADRs are broadly categorized into predictable (type A) and unpredictable (type 
B) reactions. Predictable reaction is usually dose dependent, related to the known 
pharmacologic actions of drugs, and occurs in healthy individuals. Unpredictable 
reactions are generally dose independent, are not related to the pharmacologic actions 
of drugs, and only occur in susceptible individuals. Stevens Johnson Syndrome (SJS) 
and Toxic Epidermal Necrolysis (TEN) are two fatal ADR encountered in some 
patients prescribed carbamazepine or phenytoin. US FDA had published a medical 
alert with a recommendation of HLA-B*1502 screening before these two (2) drugs 
were prescribed to patients with Asian ancestry as the likelihood of SJS/TEN were 
highly associated with HLA-B*1502. For the methods, eighty (80) healthy unrelated 
individuals and eighty six (86) patients attending clinics at Department of Neurology 
of a local hospital were recruited. DNA was extracted from blood samples obtained 
from each patient. HLA-B*1502 genotype was determined by AS-PCR developed in 
house. All statistical analysis was performed using SPSS software version 20. P 
values < 0.05 were considered statistically significant. The strength of association 
between HLA-B*1502 with CBZ-induced SJS-TEN was estimated by calculating the 
odd ratio. For the results, among the 86 patients, 40 were newly registered patients 
and genotype screening was conducted before patients were prescribed with CBZ. 
Among this group, 17.5% were positive for HLA-B*1502. In another cohort in which 
CBZ had been withdrawn due to SJS/ TEN; all of them (15) were positive for HLA-
B*1502. One patient with positive HLA-B*1502 however did not develop SJS/TEN 
and is therefore tolerant. The frequency of HLA-B*1502 allele in CBZ-SJS/TEN after 
CBZ prescribed was 32.6%. The calculated ratio of patients at risk of developing 
SJS/TEN based on this small samples size is 120.2727 (95% CI: 6.1202 - 2363.5775; 
p = 0.0016). For the conclusion, the screening of patients for the HLA-B*1502 allele 
before the initiation of carbamazepine treatment and withholding carbamazepine from 
//jL4-Z?*/502-positive patients can reduce the incidence of carbamazepine-induced 
SJS-TEN among the Malaysia. This study conclude that the implementation of HLA-
B*1502 screening is necessary to avoid patients at risk of SJS/TEN from being 
prescribed CBZ due to the high odd ratio observed in this study. 
in 
ACKNOWLEDGEMENTS 
First of all I am grateful to Almighty ALLAH S.W.T. in giving me patience, in giving 
me strength and in giving me time to complete this project. 
I would to express my special appreciation and thanks to my supervisor, Prof. Dr. Teh 
Lay Kek, for allowing me to work on this project. Thank you for your exemplary 
guidance, monitoring, support, patience, and constant encouragement throughout the 
course of this thesis. I wouldn't get through this project without you. I also would like 
to extend thanks to Prof. Dr. Mohd Zaki Salleh as Director of Integrative 
Pharmacogenomics Institute (iPROMISE) to allowing me to do the laboratory work 
and used many equipments, apparatus, and machines in this lab. The blessing, help, 
and guidance given by him time to time shall carry me a long way in the journey of 
life on which I am about to embark. 
I am obliged to all iPROMISE members, for the valuable information provided by 
them in their respective fields. I am grateful for their cooperation during the period of 
my works. Thanks to all wonderful friends that I have made in UiTM Puncak Alam. 
Last but not least, I thank my parents, Zakaria and Hamsiah, for all their prayers for 
me, who called me every weekend and asked how I was doing. Thanks a lot, mak and 
ayah. Thanks for your understanding why I wanted to get educated in Puncak Alam. I 
also would like to thank all my brothers and sisters, Saiful Azly, Rozi Aida, Ady 
Syahrizal, and Nur Azlinda for being there whenever I needed them. 
Thank you. 
iv 
TABLE OF CONTENTS 
Page 
AUTHOR'S DECLARATION 
ABSTRACT 
ACKNOWLEDGEMENTS 
TABLE OF CONTENTS 
LIST OF TABLES 
LIST OF FIGURES 
LIST OF PLATES 
LIST OF ABBREVIATIONS 
11 
iii 
iv 
v 
ix 
xi 
xiii 
xiv 
CHAPTER ONE: INTRODUCTION 
1.1 Background 
1.2 Problem Statement 
1.3 Objectives 
1.4 Scope of Study 
1.5 Significance of Study 
1 
2 
3 
3 
3 
CHAPTER TWO: LITERATURE REVIEW 
2.1 Introduction 4 
2.2 Adverse Drug Reaction (ADR) 4 
2.2.1 Epidemiology of Adverse Drug Reaction (ADR) 5 
2.2.2 Stevens Johnson Syndrome (SJS) and Toxic 6 
Epidermal Necrolysis (TEN) 
2.2.3 Epidemiology and Pathogenesis of SJS And TEN 9 
2.3 Carbamazepine (CBZ) Induced SJS/TEN 12 
2.3.1 Carbamazepine (CBZ) 12 
2.3.2 Clinical Use of Carbamazepine (CBZ) 12 
2.3.3 Side Effect of Carbamazepine (CBZ) 13 
2.4 Relationship between Hypersensitivity Reaction and HLA System 13 
